Interpol said 14,000 officers carried out Operation Liberterra III between Nov. 10 and Nov. 21. The operation across 119 countries resulted in 3,744 arrests, the protection of 4,414 potential victims ...
Hello, and welcome to the Robert Half Fourth Quarter 2025 Conference Call. Today's conference call is being recorded.
Abraaj Group invests in Vine Pharma, Uganda’s largest pharmacy chain: London Tuesday, February 5, 2013, 13:00 Hrs [IST] The Abraaj Group, a leading private equity investor opera ...
Get More information on Income Tax including breaking news and opinion. Check News articles, photos, videos of Income Tax at Indiatoday ...
Zacks Investment Research on MSN
How is Target navigating a value-focused retail landscape?
Target Corporation TGT is operating in a retail environment where consumers are increasingly focused on value, convenience ...
Threat actors are systematically hunting for misconfigured proxy servers that could provide access to commercial large language model (LLM) services. In an ongoing campaign that started in late ...
Across industries, executives are pouring unprecedented capital into data platforms, analytics, and artificial intelligence. The promise is compelling. Better insight. Faster decisions. Measurable ...
Voltalia (Euronext Paris, ISIN code: FR0011995588), an international renewable energy player, holds at the end of 2025 a total capacity of 3,554 megawatts, including 2,913 megawatts in operation ...
The company will use funding to grow its existing Product Companies, fuel the creation of new Product Companies, and pursue key corporate development opportunities. WASHINGTON, Jan. 8, 2026 ...
The U.S. is withdrawing a small number of personnel as a "precautionary measure" from a major U.S. airbase in Qatar, a U.S. official tells CBS News. The step comes amid President Trump's threats to ...
Strategy's valuation remains stretched, with the stock trading at 81.84x sales and forward EV/EBITDA of 1778. Click here to find out why I rate MSTR a Sell.
FDA accepted NDA for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC; PDUFA target action date of September 18, 2026 NDA submission for neladalkib in TKI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results